Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
RARE Ultragenyx Pharmaceutical
- 45.780
- -1.110-2.37%
Close Dec 13 16:00 ET
- 45.780
- 0.0000.00%
Post 20:01 ET
4.23BMarket Cap-7.21P/E (TTM)
47.120High45.410Low794.22KVolume46.670Open46.890Pre Close36.45MTurnover0.89%Turnover RatioLossP/E (Static)92.34MShares60.37052wk High12.19P/B4.08BFloat Cap37.02052wk Low--Dividend TTM89.11MShs Float179.647Historical High--Div YieldTTM3.65%Amplitude31.520Historical Low45.895Avg Price1Lot Size
About Ultragenyx Pharmaceutical Company
Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Company Profile
SymbolRARE
Company NameUltragenyx Pharmaceutical
Listing DateJan 31, 2014
Issue Price21.00
Founded2010
CEODr. Emil D. Kakkis, M.D.,PhD
MarketNASDAQ
Employees1276
Fiscal Year Ends12-31
Address60 Leveroni Court
CityNovato
ProvinceCalifornia
CountryUnited States of America
Zip Code94949
Phone1-415-483-8800
Websitehttp://www.ultragenyx.com
Company Executives
- Name
- Position
- Salary
- Dr. Emil D. Kakkis, M.D.,PhD
- Director, President, Chief Executive Officer
- 13.08M
- Theodore A. Huizenga
- Senior Vice President, Corporate Controller and Chief Accounting Officer
- --
- Karah Parschauer
- Chief Legal Officer and Executive Vice President, Corporate Affairs
- 4.04M
- Erik Harris
- Chief Commercial Officer and Executive Vice President
- 4.07M
- Thomas R. Kassberg
- Chief Business Officer and Executive Vice President
- --
- Dennis Karl Huang
- Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations
- --
- John Richard Pinion, II
- Chief Quality Officer and Executive Vice President, Translational Sciences
- 4.05M
- Howard Horn
- Chief Financial Officer and Executive Vice President, Corporate Strategy
- 5.94M
- Dr. Eric Crombez, M.D.
- Executive Vice President and Chief Medical Officer
- --
- Daniel G. Welch
- Chairman of the Board
- 499.89K
- Dr. Amrit Ray, M.D.
- Independent Director
- 460.39K
- Dr. Deborah L. Dunsire,M.D.
- Independent Director
- 459.89K
- Michael A. Narachi
- Independent Director
- 482.39K
- Dr. Corazon Dating Sanders, PhD
- Independent Director
- 469.39K
- Dr. Shehnaaz Suliman, M.D.
- Independent Director
- 466.89K
- Matthew K. Fust
- Independent Director
- 479.89K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.